The Ministry of Health Malaysia through the National Pharmaceutical Control Bureau (NPCB), which was set up in 1985, is the Malaysian authority that assures the quality of medicines in the country.
Malaysian guidelines for biosimilars
Home/Guidelines | Posted 05/08/2011 0 Post your comment
The NPCB is in charge of ensuring that all pharmaceutical and health products in the Malaysian market are of quality, safe and efficacious, regulated according to relevant legislations and used rationally.
In Malaysia, a biosimilar is defined as ‘a new biological medicinal product’ developed to be similar in terms of quality, safety and efficacy to an already registered, well established medicinal product’.
An abbreviated pathway for biosimilars was established and guidelines for biosimilars were published by the NPCB in July 2008.
Overarching guidelines
These guidelines cover all biosimilar products:
Guidance document and guidelines for registration of biosimilars in Malaysia
30 July 2008
portal.bpfk.gov.my/index.cfm?menuid=46&parentid=15
This document should be read in conjunction with the relevant sections of the Control of Drugs and Cosmetic Regulations 1984 (CDCR 1984) and the relevant sections of other applicable NPCB guidance documents.
The guidance document applies to biological drugs that contain well-characterised proteins, but does not cover complex biological, such as blood-derived products, vaccines, immunologicals, gene/cell therapy products, etc.
Approval of a product through the biosimilar pathway is not an indication that the biosimilar may be automatically substituted.
Related article
Malaysian guidelines for generics
Source: NPCB
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Comments (0)
Post your comment